Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Editorial Comment for Hatipoglu et al.
Krambeck, Amy E.

Journal of Endourology | July 8, 2013 | Volume: 27 | Issue: 9 | Pages: 1146-1147

10.1089/end.2013.0413 | PMID 23829539 Get It

Autologous haematopoietic cell transplantation for non‐Hodgkin lymphoma with secondary CNS involvement
Wang, Zhiwei , Zhang, Mei‐Jie , Bolwell, Brian J., Chen, Andy I. , Fenske, Timothy S. , Freytes, César O. , Gibson, John, Hayes‐Lattin, Brandon , Holmberg, Leona , Inwards, David J. , Isola, Luis , Khoury, H. Jean , Lewis, Victor , Maharaj, Dipnarine , Munker, Reinhold , Phillips, Gordon L., Rizzieri, David A. , Rowlings, Philip A., Saber, Wael , Satwani, Prakash , Waller, Edmund K. , Maloney, David G. , Montoto, Silvia , Laport, Ginna G. , Hari, Parameswaran , Holmberg, Leona , Chen, Andy , Maziarz, Richard Thomas , Gale, Robert Peter , Vose, Julie M. , Lazarus, Hillard M. , Waller, Edmund K , Montoto, Silvia , Hari, Parameswaran

British Journal of Haematology | July 6, 2013 | Volume: 162 | Issue: 5 | Pages: 648-656

10.1111/bjh.12451 | PMID 23829536 Get It

SummaryPre‐existing central nervous system (CNS) involvement may influence referral for autologous haematopoietic cell transplantation (AHCT) for patients with non‐Hodgkin lymphoma (NHL). The outcomes of 151 adult patients with NHL with prior secondary CNS involvement (CNS+) receiving an AHCT were compared to 4688 patients without prior CNS lymphoma (CNS−). There were significant baseline differences between the cohorts. CNS+ patients were more likely to be younger, have lower performance scores, higher age‐adjusted international prognostic index scores, more advanced disease stage at diagnosis, more aggressive histology, more sites of extranodal disease, and a shorter interval between diagnosis and AHCT. However, no statistically significant differences were identified between the two groups by analysis of progression‐free survival (PFS) and overall survival (OS) at 5 years. A matched pair comparison of the CNS+ group with a subset of CNS− patients matched on propensity score also showed no differences in outcomes. Patients with active CNS lymphoma at the time of AHCT (n = 55) had a higher relapse rate and diminished PFS and OS compared with patients whose CNS lymphoma was in remission (n = 96) at the time of AHCT. CNS+ patients can achieve excellent long‐term outcomes with AHCT. Active CNS lymphoma at transplant confers a worse prognosis.
Targeting heat shock proteins to modulate α-synuclein toxicity
Jones, Daryl, Moussaud, Simon , McLean, Pamela J. , Jones, Daryl Rhys, McLean, Pamela, McLean, Pamela J

Therapeutic Advances in Neurological Disorders | July 6, 2013 | Volume: 7 | Issue: 1 | Pages: 33-51

10.1177/1756285613493469 | PMID 24409201 Get It

Parkinson’s disease is a slowly progressive neurodegenerative disorder typically characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta, and the intraneuronal deposition of insoluble protein aggregates chiefly comprised of α-synuclein. Patients experience debilitating symptoms including bradykinesia, rigidity and postural instability. No curative treatment currently exists and therapeutic strategies are restricted to symptomatic treatment only. Over the past decade a class of molecular chaperones called the heat shock proteins has emerged as a potentially promising therapeutic target. Heat shock proteins aid in the folding and refolding of proteins, and target denatured proteins to degradation systems. By targeting heat shock proteins through various means including overexpression and pharmacological enhancement, researchers have shown that α-synuclein aggregation and its associated cytotoxicity can be therapeutically modulated in an array of cell and animal models. This review highlights the relevant progress in this field and discusses the relevance of heat shock proteins as therapeutic modulators of α-synuclein toxicity to the rapidly evolving understanding of Parkinson’s disease pathogenesis.
Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Anderson, S. Keith , Lafky, Jackie M., Uhm, Joon H. , Kumar, Shaji , Kimlinger, Teresa K. , Northfelt, Donald W. , Flynn, Patrick J. , Jaeckle, Kurt A. , Buckner, Jan C. , Galanis, Evanthia , Giannini, Caterina , Kaufmann, Timothy J.

Clinical Cancer Research | July 6, 2013 | Volume: 19 | Issue: 17 | Pages: 4816-4823

10.1158/1078-0432.ccr-13-0708 | PMID 23833308 Get It

Abstract Purpose: We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect. We also investigated whether VEGF, VEGFR2 and hypoxia-inducible factor-1α single-nucleotide polymorphisms (SNP), circulating biomarkers of angiogenesis, and MRI markers such as apparent diffusion coefficient (ADC) are correlated with treatment efficacy and/or toxicity. Experimental Design: Patients received bevacizumab (5 mg/kg every 2 weeks) with sorafenib (200 mg twice a day, weekly, days 1–5; group A). Due to toxicity, the starting sorafenib dose was subsequently modified to 200 mg every day (group B). Results: Fifty-four patients were enrolled: 19 patients in group A and 35 in group B. Objective response rate was 18.5% with median duration of 6.7 months (range 0.5–24.1 months). Six-month progression-free survival (PFS6) was 20.4% (11/54), and median overall survival (OS) was 5.6 months [95% confidence interval (CI), 4.7–8.2]; outcome was similar between the two dose groups. We identified SNPs in the VEGF and VEGFR2 promoter regions, which were associated with PFS6 (P < 0.022). Among molecular markers of angiogenesis, a higher log2 baseline level of stromal cell–derived factor-1 was associated with PFS6 success (P = 0.04). Circulating endothelial cells decreased during treatment with subsequent increase at disease progression (P = 0.022). Imaging analysis showed a trend associating ADC-L with poor outcome. Conclusions: The bevacizumab/sorafenib combination did not improve outcome of patients with recurrent glioblastoma versus historic bevacizumab-treated controls. Biologic markers of response and resistance to bevacizumab in gliomas were identified which merit prospective validation. Clin Cancer Res; 19(17); 4816–23. ©2013 AACR.
Fibrocalcific Aortic Valve Disease
Weiss, Robert M. , Miller, Jordan D. , Heistad, Donald D. , Miller, Jordan

Circulation Research | July 5, 2013 | Volume: 113 | Issue: 2 | Pages: 209-222

10.1161/circresaha.113.300153 | PMID 23833295 Get It

Studies in vitro and in vivo continue to identify complex-regulated mechanisms leading to overt fibrocalcific aortic valve disease (FCAVD). Assessment of the functional impact of those processes requires careful studies of models of FCAVD in vivo. Although the genetic basis for FCAVD is unknown for most patients with FCAVD, several disease-associated genes have been identified in humans and mice. Some gene products which regulate valve development in utero also protect against fibrocalcific disease during postnatal aging. Valve calcification can occur via processes that resemble bone formation. But valve calcification can also occur by nonosteogenic mechanisms, such as formation of calcific apoptotic nodules. Anticalcific interventions might preferentially target either osteogenic or nonosteogenic calcification. Although FCAVD and atherosclerosis share several risk factors and mechanisms, there are fundamental differences between arteries and the aortic valve, with respect to disease mechanisms and responses to therapeutic interventions. Both innate and acquired immunity are likely to contribute to FCAVD. Angiogenesis is a feature of inflammation, but may also contribute independently to progression of FCAVD, possibly by actions of pericytes that are associated with new blood vessels. Several therapeutic interventions seem to be effective in attenuating the development of FCAVD in mice. Therapies which are effective early in the course of FCAVD, however, are not necessarily effective in established disease.
Retrorectal cystic hamartoma: this cyst has a “tail” to tell
Gleeson, Ferga C. , Lévy, Michaël

Endoscopy | July 5, 2013 | Volume: 45 | Issue: S 02 | Pages: E191-E192

10.1055/s-0033-1344130 | PMID 23832502 Get It

Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma
Bethlenfalva-Hora, Caroline Erös de, Mertens, Joachim C. , Piguet, Anne‐Christine, Kettenbach, Joachim , Schmitt, Johannes , Terracciano, Luigi , Weimann, Rosemarie, Dufour, Jean‐François , Geier, Andreas

Clinical Science | July 5, 2013 | Volume: 126 | Issue: 3 | Pages: 243-252

10.1042/cs20130089 | PMID 23822114 Get It

RFA (radiofrequency ablation) is an established therapy for HCC (hepatocellular carcinoma). The multikinase inhibitor sorafenib prolongs survival in advanced HCC. We examined the effects of RFA alone and in combination with sorafenib on a bystanding tumour in a two-tumour rat model of HCC. A total of 80 rats were implanted with two liver tumours and randomized to four treatment groups: vehicle and sham operation (control), sorafenib and sham operation (Sora/Sham), vehicle and RFA (Vh/RFA), and sorafenib and RFA (Sora/RFA) (n=10/group per time point). RFA or sham-operation was performed on the left lobe tumour on day 15. Animals were killed at day 18 and day 30. Non-RFA-targeted right lobe tumours were analysed for angiogenesis, growth factors [HGF (hepatocyte growth factor), EGF (epidermal growth factor) and VEGF (vascular endothelial growth factor)] and infiltrating immune cells (CD3 and CD68). At day 30, the non-RFA-targeted tumours were significantly smaller in all three treatment groups compared with control (Sora/Sham P≤0.0001, Vh/RFA P=0.005 and Sora/RFA P≤0.0001). The smallest tumours were observed in animals treated with a combination of sorafenib and RFA, whereas the size reduction seen in the RFA-only group indicated an RFA-mediated distant suppression of tumour growth. Growth factor measurement revealed transiently decreased EGF levels after RFA (P=0.008), whereas sorafenib treatment decreased HGF levels (P=0.001). MVD (microvessel density) was reduced by sorafenib (P=0.002) despite increased VEGF levels (P≤0.0001). The immune parameters revealed augmented T-cells and IL-10 (interleukin 10) levels in all three treatment groups; sorafenib additionally increased macrophage numbers (P≤0.0001). RFA and sorafenib alone resulted in significant volume reduction of the non-RFA-targeted tumour; this effect was enhanced when both modalities were combined.
Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease
Zhang, Ben , Malouf, Joseph F., Young, Phillip M. , Dronca, Roxana , Kohli, Manish

Rare Tumors | July 5, 2013 | Volume: 5 | Issue: 3 | Pages: 103-105

10.4081/rt.2013.e29 | PMID 24179641 Get It

Cardiac metastasis in renal cell carcinoma is a very rare entity, with only a few previously reported cases. In this series, we report two cases of ventricular metastases from renal cell carcinoma without vena cava or right atrial involvement. The first case involves an initially isolated inoperable metastasis to the left ventricle, which was treated with systemic targeted therapy with favorable local response. Our second case illustrates a patient with an isolated cardiac metastasis in the interventricular septum with extension into the right ventricle, which has also remained stable in size on systemic targeted therapy. Although anti-angiogenic agents such as tyrosine kinase inhibitors have transformed the treatment of metastatic renal cell carcinoma in recent years, their efficacy and safety in treating patients with metastatic disease in highly vascular organs such as the heart are currently unknown, with no prior reports on this topic. We describe our novel management of these unique cases and discuss the current medical and surgical approaches to treating cardiac metastases from renal cell carcinoma.
Magnetic Resonance Imaging in Patients with Recently Implanted Pacemakers
Friedman, Hannah, Acker, Nancy, Dalzell, Connie, Shen, Win K., Asirvatham, Samuel J. , Cha, Yong‐Mei , Hodge, David O. , Felmlee, Joel P. , Watson, Robert E. , Friedman, Paul A. , Friedman, Hannah L, Asirvatham, Samuel J

Pacing and Clinical Electrophysiology | July 4, 2013 | Volume: 36 | Issue: 9 | Pages: 1090-1095

10.1111/pace.12213 | PMID 23826621 Get It

BackgroundRecent studies have shown that magnetic resonance imaging (MRI) of patients with pacemakers can be safely performed under careful monitoring, but they excluded patients with recently implanted devices. Patients with recent implants may be at a greater risk for complications during MRI imaging due to lack of lead and wound maturity.MethodsWe implemented a clinical protocol for MRI imaging of patients with implanted cardiac devices, and prospectively collected data. For this study, we retrospectively analyzed two groups of patients: those with recently implanted (≤42 days) and nonrecently implanted (>42 days) leads at the time of MRI scanning. All devices were interrogated before and after scanning, and were reprogrammed during the scan as per protocol.ResultsOf the 219 scans (in 171 patients), eight included patients with recently implanted (range: 7–36 days) and 211 with only nonrecently implanted pacemaker leads. During the scan, there were no complications in the early or late group. In one patient imaged 79 days postimplant, frequent premature ventricular complexes were noted during the scan, requiring no action. No patient reported pain during or immediately after the procedure. No clinically significant changes in function were seen at subsequent follow up (average 104 days post‐MRI). Compared to patients with nonrecently implanted leads, there was no difference in any parameter between the two groups.ConclusionsWith a strong clinical indication and with careful monitoring, MRI imaging is feasible in patients with recently implanted pacemakers, although experience is limited.
2012 ESC STEMI guidelines and reperfusion therapy
Steg, Philippe Gabríel , James, Stefan Karl , Gersh, Bernard J. , Steg, P Gabriel

Heart | July 4, 2013 | Volume: 99 | Issue: 16 | Pages: 1156-1157

10.1136/heartjnl-2013-304498 | PMID 23827860 Get It